Entia Biosciences Inc

NEW
OTCPK:ERGO (USA)  
$ 0.00010 (0%) 11:08 PM EST
At Loss
Volume:
-
Avg Vol (2M):
-
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
-
At Loss
Avg Vol (2M):
-
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Entia Biosciences Inc ( ) from 2007 to Apr 30 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Entia Biosciences stock (ERGO) PE ratio as of Apr 30 2025 is 0. More Details

Entia Biosciences Inc (ERGO) PE Ratio (TTM) Chart

To

Entia Biosciences Inc (ERGO) PE Ratio (TTM) Historical Data

Total 0
  • 1
Entia Biosciences PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data

Entia Biosciences Inc (ERGO) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.